Drug Profile
Selgantolimod - Gilead Sciences
Alternative Names: GS 9688; SLGN - Gilead SciencesLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Developer Gilead Sciences; INSERM
- Class Antivirals; Hepatoprotectants; Small molecules
- Mechanism of Action Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Hepatitis-B(Combination therapy) in Australia (PO, Tablet)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Hepatitis-B in Australia (PO, Tablet)
- 21 Jun 2023 Gilead Sciences initiates the phase I trial in Hepatitis B in Taiwan(PO)